Literature DB >> 10761955

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

P E Lipsky1, P Brooks, L J Crofford, R DuBois, D Graham, L S Simon, L B van de Putte, S B Abramson.   

Abstract

Originally suggested to function mainly in inflammatory situations, recent data have implied important roles for the cyclooxygenase-2 isoenzyme in reproductive biologic processes, renal and neurologic function, and the antithrombotic activities of endothelial cells. As cyclooxygenase-2-specific inhibitors have recently become available as analgesic and anti-inflammatory drugs, a comprehensive view of this rapidly evolving field is necessary to anticipate both the potential therapeutic benefits and toxic effects associated with these agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761955     DOI: 10.1001/archinte.160.7.913

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  22 in total

Review 1.  Etoricoxib.

Authors:  Deborah J Cochrane; Blair Jarvis; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  The role of nitric oxide in prostaglandin biology; update.

Authors:  Sangwon F Kim
Journal:  Nitric Oxide       Date:  2011-07-26       Impact factor: 4.427

3.  HIF-1α may provide only short-term protection against ischemia-reperfusion injury in Sprague-Dawley myocardial cultures.

Authors:  Siyang Wang; Xin Shao; Xiaoxue Li; Xiaojuan Su; Yongxu Huo; Chunlei Yang
Journal:  Mol Clin Oncol       Date:  2016-02-03

Review 4.  Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications.

Authors:  Daniela Salvemini; Sangwon F Kim; Vincenzo Mollace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-02-06       Impact factor: 3.619

Review 5.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

6.  Inhibition of the arachidonic acid cascade by norathyriol via blockade of cyclooxygenase and lipoxygenase activity in neutrophils.

Authors:  Mei-Feng Hsu; Chun-Nan Lin; Min-Chi Lu; Jih-Pyang Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-09       Impact factor: 3.000

Review 7.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

8.  Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies.

Authors:  Włodzimierz Matysiak; Barbara Jodłowska-Jedrych
Journal:  Protoplasma       Date:  2010-08-19       Impact factor: 3.356

9.  Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.

Authors:  Deborah Layton; Lynda V Wilton; Saad A W Shakir
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

10.  Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Authors:  Sarah Kraus; Simone Hummler; Nadir Arber; Cornelia M Ulrich; Adetunji T Toriola; Elizabeth M Poole; Dominique Scherer; Jana Kotzmann; Karen W Makar; Dina Kazanov; Lior Galazan; Inna Naumov; Anna E Coghill; David Duggan; Biljana Gigic
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.